Literature DB >> 11412577

[Risk factors of a new cardio-embolic cerebral accident in non-valvular atrial fibrillation treated with acenocoumarol].

E Vázquez Muñoz1, J Gómez Cerezo, A Fernández Pavón.   

Abstract

OBJECTIVES: To investigate the risk factors determining the appearance of a new cardio-embolic cerebral accident on secondary thrombophylaxis of non-valvular auricular fibrillation (NVAF).
DESIGN: Controlled observational study on a series of patients treated with acenocoumarol for a period of 2.8 years.
SETTING: Anticoagulation Unit of the La Paz Hospital and patients from Madrid Area 5. PARTICIPANTS: 172 patients with NVAF, over 55 and with fibrillation for at least a year, and who had suffered at least one ischaemic cerebral accident. All were treated with acenocoumarol and controlled at an INR of 2.5. The risk factors were determined and the appearance of new cardio-embolic phenomena was watched during the study period.
MEASUREMENTS AND MAIN RESULTS: 12 cardio-embolic phenomena were recorded (11 CVA and one peripheral embolism). The univariate study showed there was a significant association between patients who suffered a new ictus and those who suffered heart failure (p < 0.05) and had a history of more than one ictus before the start of the study (p < 0.05). Multivariate analysis found that what had independent predictive value was having suffered more than one ictus.
CONCLUSIONS: The greatest threat for developing a new ischaemic CVA during anticoagulation in NVAF is having a history of two or more previous ictus, as if the tendency to recur was due to these patients having more extensive atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11412577      PMCID: PMC7681727          DOI: 10.1016/s0212-6567(01)78894-4

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  11 in total

1.  Assessment of risk of thromboembolism in atrial fibrillation: which patients should be anticoagulated?

Authors:  G Y Lip
Journal:  Eur Heart J       Date:  1999-12       Impact factor: 29.983

2.  Atrial fibrillation: the epidemic of the new millennium.

Authors:  M D Ezekowitz
Journal:  Ann Intern Med       Date:  1999-10-05       Impact factor: 25.391

Review 3.  Primary and secondary stroke prevention in atrial fibrillation.

Authors:  D C Anderson
Journal:  Semin Neurol       Date:  1998       Impact factor: 3.420

4.  Risk of stroke in relation to level of blood pressure and other risk factors in treated hypertensive patients.

Authors:  Y Makino; Y Kawano; J Minami; T Yamaguchi; S Takishita
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

Review 5.  ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.

Authors:  G Y Lip; G D Lowe
Journal:  BMJ       Date:  1996-01-06

6.  Importance of left atrial appendage flow as a predictor of thromboembolic events in patients with atrial fibrillation.

Authors:  O Kamp; P M Verhorst; R C Welling; C A Visser
Journal:  Eur Heart J       Date:  1999-07       Impact factor: 29.983

7.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial.

Authors: 
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

8.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

9.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11

10.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.